/
DCTH
$17.36+$0.25 (+1.46%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$593.7M
35M shares
52-week range
$8.12 – $17.42
99% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Change+$8.62
Delcath Systems Inc
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
www.delcath.com- Employees
- 156
- IPO / List date
- Oct 19, 2000
- HQ
- QUEENSBURY, NY
Held by traders on TradeandTell
No one on the platform currently holds DCTH.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 155,300 | $1.4M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2019-12-24 | 1-for-700reverse |
| 2018-05-02 | 1-for-500reverse |
| 2017-11-06 | 1-for-350reverse |
| 2016-07-21 | 1-for-16reverse |
| 2014-04-09 | 1-for-16reverse |
Recent trades on TradeandTell
No one on the platform has traded DCTH yet.
